CBAV.MC
Strong BuyFull HouseAI neutralClínica Baviera, S.A. · Healthcare · Spain · $1.0B
EUR 55.20 -0.7% · close 5 Oct · scored 7 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Clínica Baviera is a high-return, cash-generative chain of ophthalmology clinics across Spain, Italy and Germany. It sells elective, largely self-paid procedures and pays a generous dividend (a proposed 1.57 euros gross per share). The quality is real, but a new chief executive, Luis Grávalos, is only just taking over, forward earnings estimates edged down 1.6% in the last month, and nothing in the current environment clearly accelerates growth beyond its steady pace.
ABOUT CLÍNICA BAVIERA, S.A.
Read
Clínica Baviera, S.A. operates a chain of ophthalmology clinics, specializing in refractive surgery (e.g., LASIK), cataract surgery, and other advanced eye care treatments. It holds a leading position in the European ophthalmology market due to an extensive network of clinics and a strong reputation for specialized eye care. Clínica Baviera is a market leader in elective ophthalmological treatments across Europe.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 198.4M | 224.9M | 262.6M | 301.8M | 15.0% | 321.0M |
| EPS (EUR) | 1.81 | 2.21 | 2.47 | 2.63 | 13.3% | 2.87 |
| Shares | 16.3M | 16.3M | 16.0M | 16.0M | -1.7% | 16.0M |
| Debt | 47.9M | 47.4M | 63.5M | 70.6M | 13.8% | 71.5M |
| Equity | 67.3M | 91.0M | 96.9M | 110.0M | 17.8% | — |
| Op CF | 53.4M | 57.8M | 62.5M | 76.8M | 12.9% | 77.2M |
| Inv CF | -12.6M | -44.3M | -20.9M | -45.0M | — | — |
| Fin CF | -31.4M | -24.4M | -39.7M | -36.5M | — | — |
Calmer than 77% of stocks we rank over the past year (28% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CBAV.MC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CBAV.MC | Clínica Baviera, S.A.(you) | $1.0B | 92 | Strong Buy |
| PRM.MC | Prim, S.A. | $242M | 97 | Strong Buy |
| PHM.MC | Pharma Mar, S.A. | $1.4B | 64 | Hold |
| FAE.MC | Faes Farma, S.A. | $1.6B | 63 | Hold |
| ROVI.MC | Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 78 | Buy |
| GRFS | Grifols, S.A. | $4.9B | 85 | Strong Buy |
| ALM.MC | Almirall, S.A. | $2.6B | 68 | Buy |
| RJF.MC | Laboratorio Reig Jofre, S.A. | $251M | 55 | Hold |
| ORY.MC | Oryzon Genomics S.A. | $255M | 27 | Sell |
| ATRY.MC | Atrys Health, S.A. | $240M | 20 | Strong Sell |
Peer medians: ROE 6.9% · P/E 16.6x · Gross margin 62.1%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.